A prospective analysis of 949 long-term central venous access catheters for ambulatory chemotherapy in patients with gastrointestinal malignancy

被引:75
作者
Nightingale, CE
Norman, A
Cunningham, D
Young, J
Webb, A
Filshie, J
机构
[1] ROYAL MARSDEN HOSP,DEPT ANAESTHESIA,SUTTON SM2 5PT,SURREY,ENGLAND
[2] CANC RES INST,SUTTON SM2 5PT,SURREY,ENGLAND
[3] HAMMERSMITH HOSP,DEPT ANAESTHESIA,LONDON W12 0HS,ENGLAND
[4] CANC RES CAMPAIGN,MED SECT,SUTTON SM2 5PT,SURREY,ENGLAND
[5] CANC RES CAMPAIGN,GI UNIT,SUTTON SM2 5PT,SURREY,ENGLAND
关键词
central venous; tunnelled; Hickman; chemotherapy; gastrointestinal; cancer;
D O I
10.1016/S0959-8049(96)00452-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We present a prospective analysis of the insertion complications and longevity of 949 cuffed, tunnelled central venous catheters used for ambulatory chemotherapy. Mean catheter life span was 121.8 days, 13.4% had complications at insertion, 17.7% had complications not necessitating removal and 18.6% had complications requiring removal. The more experienced operators had fewer complications inserting catheters (P < 0.0001). Late-onset shoulder pain occurred in 4.8% and was associated with an increased incidence of venous thrombosis (P < 0.0001) and infection (P = 0.06). Complications necessitating removal were not predicted by patient' age, site of insertion or malignancy, chemotherapy regimen, insertion platelet and fibrinogen counts, insertion complications, leucocyte count or cuff distance from the exit site. Catheters inserted with their tip in the superior at risk of removal (2.57 times) than those in the right atrium (P = 0.003). (C) 1997 Elsevier Science Ltd.
引用
收藏
页码:398 / 403
页数:6
相关论文
共 20 条
[1]  
ANDERSON N, 1992, CANCER, V70, P998
[2]   VERY LOW-DOSES OF WARFARIN CAN PREVENT THROMBOSIS IN CENTRAL VENOUS CATHETERS - A RANDOMIZED PROSPECTIVE TRIAL [J].
BERN, MM ;
LOKICH, JJ ;
WALLACH, SR ;
BOTHE, A ;
BENOTTI, PN ;
ARKIN, CF ;
GRECO, FA ;
HUBERMAN, M ;
MOORE, C .
ANNALS OF INTERNAL MEDICINE, 1990, 112 (06) :423-428
[3]  
DAVIS SJ, 1984, AM SURGEON, V50, P673
[4]  
FRANCESCHI D, 1989, J CARDIOVASC SURG, V30, P124
[5]  
GEMLO BT, 1988, ARCH SURG-CHICAGO, V123, P490
[6]  
GRAY RR, 1991, J INTERVENTIONAL RAD, V6, P133
[7]  
HAYWARD SR, 1990, AM SURGEON, V56, P515
[8]   ROYAL-MARSDEN PHASE-III TRIAL OF FLUOROURACIL WITH OR WITHOUT INTERFERON ALFA-2B IN ADVANCED COLORECTAL-CANCER [J].
HILL, M ;
NORMAN, A ;
CUNNINGHAM, D ;
FINDLAY, M ;
NICOLSON, V ;
HILL, A ;
IVESON, A ;
EVANS, C ;
JOFFE, J ;
NICOLSON, M ;
HICKISH, T .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (06) :1297-1302
[9]  
HURTUBISE MR, 1980, ARCH SURG-CHICAGO, V115, P212
[10]   PHASE-II STUDY OF CONTINUOUS-INFUSION FLUOROURACIL WITH EPIRUBICIN AND CISPLATIN IN PATIENTS WITH METASTATIC AND LOCALLY ADVANCED BREAST-CANCER - AN ACTIVE NEW REGIMENT [J].
JONES, AL ;
SMITH, IE ;
OBRIEN, MER ;
TALBOT, D ;
WALSH, G ;
RAMAGE, F ;
ROBERTSHAW, H ;
ASHLEY, S .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (06) :1259-1265